News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Trial sets up 2020 filing for Poxel's novel diabetes drug French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.